Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

     Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

PR Newswire

WASHINGTON, Aug. 6, 2013

WASHINGTON, Aug. 6, 2013 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda)
(NASDAQ: VNDA) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. The offering is subject to
market conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering.
Vanda also expects to grant the underwriters a 30-day option to purchase up to
an additional 15% of the shares of common stock offered in the public offering
to cover over-allotments, if any. All of the shares in the offering are to be
sold by Vanda, with net proceeds to be used for sales and marketing
expenditures which may include commercial launch activities for tasimelteon
for the treatment of Non-24-Hour Disorder following the receipt of regulatory
approval, if any, research and development activities and other general
corporate purposes.

Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as the joint
book-running managers of the offering.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (SEC) and declared effective by the SEC on February 11,
2011. A preliminary prospectus supplement relating to and describing the terms
of the offering will be filed with the SEC and will be available on the SEC's
web site at When available, copies of the preliminary prospectus
supplement relating to these securities may also be obtained from the offices
of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York,
NY, 10020 or via telephone at (800)542-0970 or the offices of Piper Jaffray &
Co., by mail at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone
at (800) 747-3924 or by e-mail at

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any of these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of products for the treatment of central
nervous system disorders. For more information on Vanda, please visit

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect Vanda's future operating
results and financial position. Such statements, including, but not limited
to, those regarding statements about Vanda's expectations regarding its
fundraising efforts, including the closing of the public offering and the
underwriter's exercise of its over-allotment option, involve known and unknown
risks that relate to Vanda's future events or future financial performance and
the actual results could differ materially from those discussed in this
communication. Risks and uncertainties that may cause Vanda's actual results
to differ materially from those discussed in this communication can be found
in the "Risk Factors" section of Vanda's Form 10-K, Forms 10-Q and its other
filings with the Securities and Exchange Commission. Readers are cautioned not
to place undue reliance on these forward-looking statements that speak only as
of the date hereof, and Vanda assumes no responsibility to update or revise
any forward-looking statements contained in this communication to reflect
events, trends or circumstances after the date of this communication.

Company Contact:

Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

Media Contact:

Laney Landsman
Assistant Vice President
(212) 508-9643

SOURCE Vanda Pharmaceuticals Inc.

Press spacebar to pause and continue. Press esc to stop.